Interested in promotions? | Click here >>
54678
LY-364947
Activators & Inhibitors
Chemical Modulators

LY-364947 #54678

Reviews ()
Citations (0)

Western blot analysis of extracts from HT-1080 cells, untreated (-) or treated with Human Transforming Growth Factor β1 (hTGF-β1) #8915 (10 ng/ml, 30 min; +) with or without pretreating the cells with LY-364947 (1 μM, 1 hr; +), using Phospho-Smad2 (Ser465/467)/Smad3 (Ser423/425) (D27F4) Rabbit mAb #8828 (upper), Smad2/3 (D7G7) XP® Rabbit mAb #8685 (middle), and β-Actin (D6A8) Rabbit mAb #8457 (lower).

Chemical structure of LY-364947.

Product Usage Information

LY-364947 is supplied as a lyophilized powder. For a 15 mM stock, reconstitute 5 mg of powder in 1.22 ml of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.

Storage

Store lyophilized at room temperature, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Product Description

Molecular Weight: 272.3 g/mol

Purity: >98%

Molecular Formula: C17H12N4

CAS: 396129-53-6

Solubility: Soluble in DMSO at 25 mg/ml.

Background

LY-364947, also known as HTS-466284, is a potent and selective TGF-β type-I receptor (TGF-β RI, TGFR-I, TβR-I, ALK-5) inhibitor. This small molecule specifically targets TGF-β RI with an IC50 value of 59 nM and is less effective on TGF-β RII and MLK-7K (IC50 values of 400 nM and 1400 nM, respectively) (1). LY-364947 regulates MDA-MB-231 cell invasion by inhibiting autocrine TGF-β signaling (2). Patients in intensive care units (ICUs) that suffer from chronic sepsis can experience weakening of the diaphragm muscles caused by muscle wasting, requiring mechanical ventilation. Members of the TGF-β family can trigger the activation of protein breakdown. Inhibition of the TGF-β pathway can protect the diaphragm during chronic sepsis, making LY-364947 an interesting compound to study as it relates to effective ICU patient care (3).

  1. Sawyer, J.S. et al. (2003) J Med Chem 46, 3953-6.
  2. Shiou, S.R. et al. (2006) J Biol Chem 281, 33971-81.
  3. Jude, B. et al. (2019) Shock , doi: 10.1097/SHK.0000000000001393.
For Research Use Only. Not For Use In Diagnostic Procedures.

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
XP is a registered trademark of Cell Signaling Technology, Inc.

To Purchase # 54678S
Product # Size Price
54678S
5 mg $ 119